Medical Innovation Exchange

Facing €200M phase 3 bill, Abivax sells stock at knockdown price to keep lights on into next year

https://www.fiercebiotech.com/biotech/facing-eu200m-phase-3-bill-abivax-sells-stock-knockdown-price-keep-lights-next-year

Leave a Comment

Your email address will not be published.

Leave the field below empty!